Interleukin-6 (IL-6) could be one of the most critical factors for MM survival and proliferation, and also the best explanation of SFM-DR and has been implicated for resistance to various therapeutic agents, including bortezomib, glucosteroid, and other agents [58]. The gene discussed is IL6; the disease is Miyoshi myopathy.